Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.

Saved in:
Bibliographic Details
Title: Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.
Authors: Cheng HH; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: hhcheng@uw.edu., Callis S; SWOG Cancer Research Network, Seattle, WA, USA., Yu EY; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Delacroix SE; Gulf South NCORP, Mary Bird Perkins Cancer Center, Metairie, LA, USA., Sokolova AO; Oregon Health Sciences University, Portland, OR, USA., Tangen CM; SWOG Cancer Research Network, Seattle, WA, USA., Lerner SP; Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA., Dorff TB; City of Hope, Duarte, CA, USA., Lin DW; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Urology, University of Washington, Seattle, WA, USA.
Source: European urology focus [Eur Urol Focus] 2026 Jan; Vol. 12 (1), pp. 16-18. Date of Electronic Publication: 2025 Dec 06.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101665661 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2405-4569 (Electronic) Linking ISSN: 24054569 NLM ISO Abbreviation: Eur Urol Focus Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2405-4569
DOI:10.1016/j.euf.2025.11.011